Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Recrutement en coursÉtude observationnelleVolontaires sains bienvenus

Âges de 40 à 75 · Tous sexes · Mis à jour le 2 oct. 2026 · NCT05334069

Family Communications After Genetic Testing

Glens Falls Hospital, Glens Falls

Recrutement en coursVolontaires sains bienvenus

Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT07143487

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #60, New York
Exelixis Clinical Site #6, New York
Exelixis Clinical Site #76, Syracuse

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT05176483

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06625775

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Kings County Hopsital Center, Brooklyn
Queens Cancer Center of Queens Hospital, Jamaica
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
et 1 autres

Recrutement en cours

Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT04751435

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Memorial Sloan-Kettering Cancer Center, New York
New York Cancer & Blood Specialists, Shirley

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT06324357

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT05877599

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Perlmutter Cancer Center at NYU Langone Health (contact for more locations), New York

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT07659795

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Montefiore Medical Center-Einstein Campus, The Bronx
Montefiore Medical Center-Weiler Hospital, The Bronx
Montefiore Medical Center - Moses Campus, The Bronx

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT05803382

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NYOH Albany Cancer Center, Albany
Hematology-Oncology Associates of Central New York, PC, Auburn
North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Babylon
et 12 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 28 sept. 2026 · NCT07222800

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06428409

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NYU Langone Long Island Clinical Research Associates, New York
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT05379595

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site, New Hyde Park

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT07277270

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, New York
Research Site, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06218914

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NYU Langone Medical Center, New York

Recrutement en coursÉtude observationnelle

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT04981119

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Perlmutter Cancer Center at NYU Long Island, Mineola
NYU Langone Medical Center NYU Hematology Associates, New York
New York Cancer and Blood Specialists, Shirley
et 2 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Perlmutter Cancer Center at NYU Long Island, Mineola
Mount Sinai, New York
Mount Sinai West, New York
et 5 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06662786

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, East White Plains
et 3 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT05863195

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
Laura and Isaac Perlmutter Cancer Center at NYU Langone, Mineola
New York Cancer and Blood Specialists, Shirley

Recrutement en coursPhase 2/3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 23 sept. 2026 · NCT07221357

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site, Commack

Recrutement en coursPhase 2

Âges de 18 à 130 · Tous sexes · Mis à jour le 23 sept. 2026 · NCT05489211

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
et 1 autres

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07227636

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Columbia University, New York
NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

New York University (NYU) Langone Medical Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07114601

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Northwell Health / RJ Zuckerberg Cancer Center, Lake Success
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center Main Campus, New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06445062

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07213791

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NYU Langone Health Perlmutter Cancer Center, New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 21 sept. 2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 17 sept. 2026 · NCT07349537

Tislelizumab in People With Colorectal Cancer

Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 17 sept. 2026 · NCT06529523

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1/2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 16 sept. 2026 · NCT05786924

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Icahn School of Medicine At Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Ny Cancer and Blood Specialists, Shirley
et 1 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 15 sept. 2026 · NCT07284849

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park
New York Cancer and Blood Specialists-Central Park Hematology & Oncology, New York
New York Cancer & Blood Specialists, Port Jefferson Station
et 1 autres

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 11 sept. 2026 · NCT04929223

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

White Plains Hospital Medical and Wellness PRIME, White Plains

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 9 sept. 2026 · NCT07549412

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Clinical Study Site, Mineola
Clinical Study Site, New York
Clinical Study Site, Rochester
et 3 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 8 sept. 2026 · NCT07228832

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NYU Langone Health - Long Island, Mineola
New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1

Âges de 18 ans et plus · Tous sexes · Mis à jour le 4 sept. 2026 · NCT06400472

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center, New York

Recrutement en coursPhase 1

Âges de 18 à 99 · Tous sexes · Mis à jour le 1 sept. 2026 · NCT06983743

Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.